405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)
Rachel Sanborn, Ralph Hauke, Nashat Gabrail, Mark O’Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Mark Rogalski, Diego Alvarado, Laura Vitale, Tibor Keler, Michael Yellin
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A246; DOI: 10.1136/jitc-2020-SITC2020.0405
